Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh · Delayed Price · Currency is BDT 216.90
-0.10 (-0.05%)
At close: Jun 16, 2026
DSE:SQURPHARMA Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, DSE:SQURPHARMA stock has a consensus rating of "Strong Buy" and an average price target of ৳352.20. The average 1-year stock price forecast is 62.38% higher than the current stock price, while the lowest is ৳277.60 (+27.99%) and the highest is ৳425.00 (+95.94%).
Price Target: ৳352.20 (+62.38%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DSE:SQURPHARMA stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
85.11B
from 76.29B
Increased by 11.57%
Revenue Next Year
95.26B
from 85.11B
Increased by 11.93%
EPS This Year
29.93
from 27.04
Increased by 10.69%
EPS Next Year
34.52
from 29.93
Increased by 15.32%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is BDT.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 86.5B | ||
| Avg | 85.1B | ||
| Low | 84.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.3% | ||
| Avg | 11.6% | ||
| Low | 10.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 29.93 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 10.7% | ||
| Low | - |